more

Cytokinetics (CYTK)

(Delayed Data from NSDQ)

$66.82 USD

+1.25 (1.91%)

Updated Apr 24, 2024 04:00 PM ET

After-Market: $66.82 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank	Definition	Annualized Return
1	Strong Buy	24.20%
2	Buy	18.04%
3	Hold	9.52%
4	Sell	5.20%
5	Strong Sell	2.60%
S&P	500	11.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5 3

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score	A
Growth Score	A
Momentum Score	A
VGM Score	A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value D Growth A Momentum F VGM

Industry Rank:

Top 31% (78 out of 252)

Industry: Medical - Biomedical and Genetics

View All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Biotech Stock Roundup: BIIB & CNAT Crash on Study Failures, LXRX Gets CRL

by Zacks Equity Research Published on March 27,2019

Key highlights of the past week are multiple study failures and other pipeline updates.

biotechs

Amgen Starts Phase III Enrollment for Heart Failure Drug

by Zacks Equity Research Published on February 22,2019

Amgen (AMGN) and partners started enrollment for the second phase III study of omecamtiv mecarbil, which is being developed for the potential treatment of heart failure with reduced ejection fraction.

biotechs

Cytokinetics (CYTK) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research Published on February 21,2019

Cytokinetics (CYTK) delivered earnings and revenue surprises of 12.73% and 171.40%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?

CYTKPositive Net Change

The Zacks Analyst Blog Highlights: BioDelivery, Cytokinetics, Celldex, Aduro and Aeterna

by Zacks Equity Research Published on February 14,2019

The Zacks Analyst Blog Highlights: BioDelivery, Cytokinetics, Celldex, Aduro and Aeterna

pharmaceuticals

Will Cytokinetics (CYTK) Report Negative Earnings Next Week? What You Should Know

by Zacks Equity Research Published on February 14,2019

Cytokinetics (CYTK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

CYTKPositive Net Change

5 Tiny Biotech Stocks With Superb Growth Potential

by Swarup Gupta Published on February 13,2019

A spurt in deal-making has boosted the sector this year which retains the ability to provide outsized gains.

Cytokinetics Sees Hammer Chart Pattern: Time to Buy?

by Zacks Equity Research Published on November 20,2018

Cytokinetics has been struggling lately, but the selling pressure may be coming to an end soon.

CYTKPositive Net Change

medical

Cytokinetics (CYTK) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research Published on November 01,2018

Cytokinetics (CYTK) delivered earnings and revenue surprises of 24.53% and 377.18%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?

CYTKPositive Net Change

Cytokinetics (CYTK) Q3 Earnings Preview: What to Know Ahead of the Release

by Zacks Equity Research Published on October 25,2018

Cytokinetics (CYTK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

CYTKPositive Net Change

Cytokinetics (CYTK) Q3 Earnings Preview: What to Watch Ahead of the Release

by Zacks Equity Research Published on October 18,2018

Cytokinetics (CYTK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

CYTKPositive Net Change

Are Options Traders Betting on a Big Move in Cytokinetics (CYTK) Stock?

by Zacks Equity Research Published on June 05,2018

Investors in Cytokinetics (CYTK) need to pay close attention to the stock based on moves in the options market lately.

CYTKPositive Net Change

Biotech Stock Roundup: RARE drug Gets FDA Nod, Acorda, Cytokinetics Hit by Pipeline Setbacks

by Arpita Dutt Published on November 22,2017

FDA approval for Ultragenyx's (RARE) rare disease drug and pipeline setbacks faced by Acorda and Cytokinetics were the main news this week in the biotech sector.